Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030869 | 0.94 | HCRTR1 (0.31) | HCRTR1HCRTR2ALDH1A1KDM4EHPGD | |
| SCHEMBL31114908 | 0.94 | HCRTR1 (0.31) | HCRTR1HCRTR2ALDH1A1KDM4EHPGD | |
| SCHEMBL20101219 | 0.93 | HRH3 (0.31) | KDM4EHPGDHSD17B10 | |
| SCHEMBL31114847 | 0.91 | CNR1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL20101222 | 0.90 | PSD (0.32) | HCRTR1HCRTR2ALDH1A1KDM4EHPGD | |
| SCHEMBL31114861 | 0.90 | MAP3K12 (0.31) | — | |
| SCHEMBL20030766 | 0.90 | HCRTR1 (0.30) | HCRTR1HCRTR2 | |
| SCHEMBL20030688 | 0.90 | MAP3K12 (0.31) | — | |
| SCHEMBL20101157 | 0.89 | PSD (0.30) | ALDH1A1PSDLMNAMAPTTDP1 | |
| SCHEMBL20030768 | 0.88 | KDM4E (0.32) | KDM4EHPGDHSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | HCRTR1 3644/4885HCRTR2 4127/4885ALDH1A1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.